Rapport Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Net Income	-107.28	-111.48	-78.31	-34.79
Depreciation & Amortization	1	1.02	0.84	0.11
Stock-Based Compensation	21.78	18.86	10.24	3.53
Other Adjustments	1.03	0.64	4.82	1.32
Change in Receivables	-0.06	-	-	-
Changes in Accounts Payable	4.34	2.22	-0.35	0.86
Changes in Accrued Expenses	2.34	6.17	0.37	5.38
Changes in Other Operating Activities	-3.45	-4.88	-2.44	-3.58
Operating Cash Flow	-80.3	-87.47	-64.83	-27.18
Capital Expenditures	-0.41	-0.62	-2.41	-1.64
Purchases of Investments	-341.92	-354.78	-377.53	-77.22
Proceeds from Sale of Investments	171.77	167.93	209.8	-
Investing Cash Flow	-170.56	-187.47	-170.14	-78.86
Issuance of Common Stock	2.15	270.79	157.71	0.05
Repurchase of Common Stock	-0.01	-0	-	-0
Net Common Stock Issued (Repurchased)	2.15	270.79	157.71	0.05
Issuance of Preferred Stock	-	-	63.91	145.22
Net Preferred Stock Issued (Repurchased)	-	-	63.91	145.22
Other Financing Activities	-0.34	-	-	-0.13
Financing Cash Flow	271.31	270.79	221.63	145.14
Net Cash Flow	20.45	-4.16	-13.34	39.1
Free Cash Flow	-80.71	-88.09	-67.23	-28.82
FCF Margin	-403.54%	-	-	-
Free Cash Flow Per Share	-1.93	-2.26	-3.24	-19.14
Levered Free Cash Flow	-103.46	-107.58	-82.29	-33.66
Unlevered Free Cash Flow	-118.39	-121.2	-87.04	-35.06

SEC Filings: 10-K · 10-Q